Human genomics: The genome finishers.

The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86

Active transposition in genomes. Annu Rev Genet (2012) 1.51

The bat genome: GC-biased small chromosomes associated with reduction in genome size. Chromosoma (2013) 0.75

Initial sequencing and analysis of the human genome. Nature (2001) 212.86

Finishing the euchromatic sequence of the human genome. Nature (2004) 41.40

A vision for the future of genomics research. Nature (2003) 14.06

A common inversion under selection in Europeans. Nat Genet (2005) 13.66

Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet (2006) 10.36

A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. Nat Genet (2006) 5.92

Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet (2006) 5.59

Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics (2008) 4.25

Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42

The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42

Closing gaps in the human genome using sequencing by synthesis. Genome Biol (2009) 1.46

NIH faces marching orders on orphan drug shortage. Nat Med (2011) 1.70

Big pharma moves from 'blockbusters' to 'niche busters'. Nat Med (2010) 1.68

First 'breakthrough' drugs designated, but dilution worries linger. Nat Med (2013) 1.46

Cancer reproducibility project releases first results. Nature (2017) 1.45

The knockout rat pack. Nat Med (2010) 1.44

Survey details stem cell clinics ahead of regulatory approval. Nat Med (2010) 1.42

The myopia boom. Nature (2015) 1.31

Personalized investigation. Nat Med (2010) 1.29

Sequencing of superbugs seen as key to combating their spread. Nat Med (2010) 1.17

Mutation-specific cystic fibrosis treatments on verge of approval. Nat Med (2011) 1.11

Call in the backup. Nat Med (2012) 1.10

Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med (2014) 1.08

Targeting hotspots of transmission promises to reduce malaria. Nat Med (2010) 1.05

African networks launch to boost clinical trial capacity. Nat Med (2010) 1.00

Collins sets out his vision for the NIH. Nature (2009) 0.98

Mouse library set to be knockout. Nature (2011) 0.98

Phylogeny: Rewriting evolution. Nature (2012) 0.98

Syrian gas attack reinforces need for better anti-sarin drugs. Nat Med (2013) 0.96

Companies hope for kinase inhibitor JAKpot. Nat Rev Drug Discov (2011) 0.93

Spinal muscular atrophy approval boosts antisense drugs. Nat Biotechnol (2017) 0.92

Trial failure prompts soul-searching for critical-care specialists. Nat Med (2012) 0.90

Drug discoverers chart path to tackling data irreproducibility. Nat Rev Drug Discov (2014) 0.89

Venerable brain-cancer cell line faces identity crisis. Nature (2016) 0.89

Putting stem cells to the test. Nat Med (2010) 0.88

Medical devices: Managed by machine. Nature (2012) 0.88

Patent-free pact pushes the boundaries of precompetitive research. Nat Med (2014) 0.87

Old mice require new experimental tricks to study aging process. Nat Med (2013) 0.87

Rapid antidepressant effects of ketamine ignite drug discovery. Nat Med (2013) 0.87

Drug pipeline is flush with new options for chronic constipation. Nat Med (2012) 0.86

Anti-IL-5 biologics carve out severe-asthma niche. Nat Biotechnol (2014) 0.86

Chronic controversy continues over mysterious XMRV virus. Nat Med (2010) 0.86

Publication checklist proposed to boost rigor of pilot trials. Nat Med (2013) 0.86

The ultimate endpoint. Nat Med (2012) 0.85

Research technique: the murine candidate. Nature (2011) 0.84

Time to ditch stand-alone stem cell oversight panels, experts say. Nat Med (2013) 0.84

An act of tolerance. Nat Med (2012) 0.84

Trial networks move beyond single-disease strategies. Nat Med (2011) 0.84

'Game changer' antibiotic and others in works for superbug. Nat Med (2011) 0.84

Failed Alzheimer's trial does not kill leading theory of disease. Nature (2016) 0.83

Nonprofit disease groups earmark grants for drug repositioning. Nat Med (2011) 0.83

New data protection rules could harm research, science groups say. Nat Med (2014) 0.83

Cancer's true breakthroughs. Nat Med (2013) 0.83

The inverse of immunity. Nat Med (2010) 0.83

Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov (2014) 0.82

Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov (2015) 0.82

From spinach scare to cancer care. Nat Med (2011) 0.82

Antidotes edge closer to reversing effects of new blood thinners. Nat Med (2013) 0.82

Fluctuating baseline pain implicated in failure of clinical trials. Nat Med (2010) 0.82

Pharmacogenetic tests yield bonus benefit: better drug adherence. Nat Med (2013) 0.82

A history of drugs on the weight list. Nat Med (2012) 0.81

Flaw in induced-stem-cell model. Nature (2011) 0.81

Companies race to develop first Hedgehog inhibitor cancer drug. Nat Med (2011) 0.81

As E. coli continues to claim lives, new approaches offer hope. Nat Med (2011) 0.81

The sticking point. Nat Med (2013) 0.81

Early clinical data raise the bar for hemophilia gene therapies. Nat Biotechnol (2016) 0.81

Taking tissue engineering to heart. Nat Med (2011) 0.81

Deprivation: a wake-up call. Nature (2013) 0.81

Hantavirus treatments advance amidst outbreak in US park. Nat Med (2012) 0.80

Immunology: Oral solutions. Nature (2014) 0.80

Clinical efficacy data on gene tests trails marketing in psychiatry. Nat Med (2012) 0.79

This is your brain online: the Functional Connectomes Project. Nat Med (2010) 0.79

Trial puts niacin--and cholesterol dogma--in the line of fire. Nat Med (2011) 0.79

Heat shock and awe. Nat Med (2011) 0.79

FDA clearance paves way for computerized ADHD monitoring. Nat Med (2014) 0.79

Antidotes progress for new oral clotbusters. Nat Biotechnol (2015) 0.78

Talkin' 'bout my (third) generation. Nat Med (2010) 0.78

Embryonic stem cell lines given the go-ahead. Nat Med (2010) 0.78

Massive biobank yields first results--with more to come. Nat Med (2011) 0.78

Technology: Dressed to detect. Nature (2014) 0.78

Preemptive genotyping trialed to prevent adverse drug reactions. Nat Med (2011) 0.78

Gene therapies advance, but some see manufacturing challenges. Nat Med (2012) 0.78

Cancer metastasis scrutinized. Nature (2009) 0.78

Animalgesic effects. Nat Med (2010) 0.78

Jewish genetic screening grows despite questions about breadth. Nat Med (2011) 0.77

Business: The billion-dollar biotech. Nature (2015) 0.77

When it takes two to tango, FDA suggests a new regulatory dance. Nat Med (2011) 0.77

New, intensive trials planned on heels of Mississippi HIV 'cure'. Nat Med (2013) 0.77

Sequencing reveals suite of commensal and pathogenic viruses. Nat Med (2011) 0.77

Adaptive methods help drug sponsors find best treatment dose. Nat Med (2014) 0.77

Sugar treatment doesn't pacify those concerned about preemies. Nat Med (2010) 0.77

Good vibrations. Nat Med (2011) 0.77

Animal testing alternatives come alive in US. Nat Med (2010) 0.77

Sound medicine. Nat Med (2012) 0.77

Antibody drugs set to revive flagging migraine target. Nat Rev Drug Discov (2013) 0.77

Animal rule for drug approval creates a jungle of confusion. Nat Med (2013) 0.77

Cancer immunotherapy advances spawn calls for new endpoints. Nat Med (2013) 0.77

Four-strain flu vaccines coming to a pharmacy near you. Nat Med (2012) 0.77

NIH accused of being overly literal on stem cell approvals. Nat Med (2012) 0.76

Inner Workings: Combating antibiotic resistance from the ground up. Proc Natl Acad Sci U S A (2016) 0.76

New technologies aim to take cancer out of circulation. Nat Med (2011) 0.76

Cancer vaccines: Material breach. Nature (2013) 0.76

To serve and neuroprotect. Nat Med (2012) 0.76

Trial designs for vaccines adapt to the times. Nat Med (2012) 0.76

Patents draw new lines in the battle to commercialize stem cells. Nat Med (2010) 0.76

Gene flaw found in induced stem cells. Nature (2010) 0.76

Underestimate of HIV reservoirs threatens purging approach. Nat Med (2013) 0.76

As leukemia options grow, drugs jockey to be first-line therapies. Nat Med (2013) 0.76

Technology: Barriers to misuse. Nature (2015) 0.75

Devices: Artificial inspiration. Nature (2012) 0.75

Behind the paper: stepping up to the antiplatelet. Nat Med (2011) 0.75